U.S. Markets close in 3 hrs 54 mins
  • S&P 500

    3,309.51
    -81.17 (-2.39%)
     
  • Dow 30

    26,808.37
    -654.82 (-2.38%)
     
  • Nasdaq

    11,119.30
    -312.05 (-2.73%)
     
  • Russell 2000

    1,554.61
    -35.87 (-2.26%)
     
  • Crude Oil

    37.43
    -2.14 (-5.41%)
     
  • Gold

    1,883.00
    -28.90 (-1.51%)
     
  • Silver

    23.48
    -1.09 (-4.46%)
     
  • EUR/USD

    1.1759
    -0.0030 (-0.2587%)
     
  • 10-Yr Bond

    0.7730
    -0.0050 (-0.64%)
     
  • Vix

    38.32
    +4.97 (+14.90%)
     
  • GBP/USD

    1.2993
    -0.0048 (-0.3664%)
     
  • USD/JPY

    104.3200
    -0.1740 (-0.1665%)
     
  • BTC-USD

    13,204.08
    -491.21 (-3.59%)
     
  • CMC Crypto 200

    261.14
    -11.55 (-4.24%)
     
  • FTSE 100

    5,571.46
    -157.53 (-2.75%)
     
  • Nikkei 225

    23,418.51
    -75.79 (-0.32%)
     

Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 22nd Annual Global Investment Conference

Verrica Pharmaceuticals
·2 mins read

WEST CHESTER, Pa., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will present a business overview at the H.C. Wainwright 22nd Annual Global Investment Conference, taking place virtually on Tuesday, September 15, 2020, at 2:00 p.m. ET.

A live webcast of the event can be accessed in the Investors/Presentations & Events section of the Verrica website at http://www.verrica.com. The webcast replay will be available shortly after conclusion of the event for 30 days.

About Verrica Pharmaceuticals Inc.

Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. The Company’s late-stage product candidate, VP-102, is a potential first-in-class topical therapy for the treatment of molluscum contagiosum. Verrica submitted an NDA for VP-102 for the treatment of molluscum in September 2019. A Complete Response Letter was received from the FDA regarding the NDA for VP-102 on July 13, 2020. If approved, VP-102 will be marketed in the United States under the conditionally accepted brand name YCANTH™. In addition, Verrica has successfully completed a Phase 2 study of VP-102 for the treatment of common warts and is currently conducting a Phase 2 study of VP-102 for the treatment of external genital warts. The Company is also developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. For more information, visit www.verrica.com.

CONTACT: FOR MORE INFORMATION, PLEASE CONTACT: Investors: A. Brian Davis Chief Financial Officer 484.453.3300 ext. 103 info@verrica.com William Windham Solebury Trout 646.378.2946 wwindham@troutgroup.com Media: Zara Lockshin Solebury Trout 646.378.2960 zlockshin@troutgroup.com